10x Genomics financials
$90.04+1.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.0M | $150.8M | $166.0M | $149.0M | $172.9M | $154.9M | $165.0M | $151.7M | $153.1M | $141.0M | $184.0M | $153.6M |
| Gross profit | $112.5M | $106.2M | $113.0M | $100.3M | $125.1M | $105.4M | $111.0M | $106.4M | $104.2M | $92.9M | $115.8M | $95.5M |
| Gross margin | 74.5% | 70.4% | 68.1% | 67.3% | 72.3% | 68.1% | 67.2% | 70.2% | 68.1% | 65.9% | 62.9% | 62.2% |
| Operating income | -$19.6M | -$17.0M | -$19.5M | -$32.2M | $30.1M | -$39.3M | -$49.8M | -$41.5M | -$41.7M | -$61.5M | -$55.2M | -$94.8M |
| Net income | -$17.9M | -$13.5M | -$16.3M | -$27.5M | $34.5M | -$34.4M | -$49.0M | -$35.8M | -$37.9M | -$59.9M | -$49.0M | -$93.0M |
| Net margin | −11.9% | −8.9% | −9.8% | −18.4% | 20.0% | −22.2% | −29.7% | −23.6% | −24.8% | −42.5% | −26.6% | −60.5% |
| Diluted EPS | $-0.14 | $-0.10 | $-0.13 | $-0.22 | $0.28 | $-0.28 | $-0.40 | $-0.30 | $-0.32 | $-0.50 | $-0.41 | $-0.79 |
| EBITDA | -$13.3M | -$7.1M | -$9.5M | -$21.9M | -$2.8M | -$40.5M | -$41.1M | -$32.5M | -$35.1M | -$50.0M | -$43.5M | -$83.4M |
| Operating cash flow | $17.0M | $26.1M | $40.8M | $43.2M | $17.7M | $34.4M | -$6.7M | $21.6M | $7.5M | -$15.7M | $25.8M | -$25.3M |
| Free cash flow | $15.4M | $24.5M | $33.9M | $33.9M | $16.1M | $32.5M | -$9.5M | $17.8M | $4.6M | -$18.6M | $22.3M | -$40.5M |
| Diluted shares | 130.0M | 128.3M | 126.4M | 125.5M | 124.5M | 122.6M | 121.6M | 120.7M | 120.1M | 119.4M | 118.6M | 117.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $502.5M | $490.3M | $474.0M | $432.5M | $397.7M | $377.1M |
| Short-term investments | $49.5M | $49.6M | $49.4M | $49.6M | $49.5M | $49.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.03B | $1.02B | $1.04B | $1.03B | $980.0M | $903.4M |
| Total liabilities | $204.5M | $201.4M | $245.0M | $242.2M | $206.7M | $196.5M |
| Shareholders' equity | $825.5M | $814.3M | $796.3M | $785.1M | $773.3M | $706.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology